NCT06815575View on ClinicalTrials.gov

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

January 31, 2029

Conditions

Solid TumoursAdvanced Solid Tumours

Interventions

DRUG

RC220

Administered by intravenous infusion over 60 minutes.

DRUG

Doxorubicin (Adriamycin)

60 mg/m2 administered by intravenous infusion over 10 minutes following adminstration of intravenous RC220 on Day 1 of the combination cycles.

Trial Locations (5)

2228

RECRUITING

Cancer Care Foundation, Miranda

2250

RECRUITING

Gosford Hospital, Gosford

2259

RECRUITING

Wyong Hospital, Wyong

999077

RECRUITING

Queen Mary Hospital, Hong Kong

Unknown

NOT_YET_RECRUITING

Prince of Wales Hospital, Shatin

All Listed Sponsors

lead

Race Oncology Ltd

INDUSTRY

NCT06815575 - A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. | Biotech Hunter | Biotech Hunter